Global Acute Hepatic Porphyria Drug Market Research Report 2023
Acute hepatic porphyria drugs are used for the treatment of adult patients with acute hepatic porphyria.
According to QYResearch’s new survey, global Acute Hepatic Porphyria Drug market is projected to reach US$ 5 million in 2029, increasing from US$ 4 million in 2022, with the CAGR of 5.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Acute Hepatic Porphyria Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Acute Hepatic Porphyria Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Acute Hepatic Porphyria Drug market is projected to reach US$ 5 million in 2029, increasing from US$ 4 million in 2022, with the CAGR of 5.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Acute Hepatic Porphyria Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Acute Hepatic Porphyria Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Alnylam Pharmaceuticals
- Recordati Rare Diseases
- 350 Mg
- 313 Mg
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 350 Mg
1.2.3 313 Mg
1.3 Market by Application
1.3.1 Global Acute Hepatic Porphyria Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Acute Hepatic Porphyria Drug Market Perspective (2018-2029)
2.2 Acute Hepatic Porphyria Drug Growth Trends by Region
2.2.1 Global Acute Hepatic Porphyria Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Acute Hepatic Porphyria Drug Historic Market Size by Region (2018-2023)
2.2.3 Acute Hepatic Porphyria Drug Forecasted Market Size by Region (2024-2029)
2.3 Acute Hepatic Porphyria Drug Market Dynamics
2.3.1 Acute Hepatic Porphyria Drug Industry Trends
2.3.2 Acute Hepatic Porphyria Drug Market Drivers
2.3.3 Acute Hepatic Porphyria Drug Market Challenges
2.3.4 Acute Hepatic Porphyria Drug Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Acute Hepatic Porphyria Drug Players by Revenue
3.1.1 Global Top Acute Hepatic Porphyria Drug Players by Revenue (2018-2023)
3.1.2 Global Acute Hepatic Porphyria Drug Revenue Market Share by Players (2018-2023)
3.2 Global Acute Hepatic Porphyria Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Hepatic Porphyria Drug Revenue
3.4 Global Acute Hepatic Porphyria Drug Market Concentration Ratio
3.4.1 Global Acute Hepatic Porphyria Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Hepatic Porphyria Drug Revenue in 2022
3.5 Acute Hepatic Porphyria Drug Key Players Head office and Area Served
3.6 Key Players Acute Hepatic Porphyria Drug Product Solution and Service
3.7 Date of Enter into Acute Hepatic Porphyria Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ACUTE HEPATIC PORPHYRIA DRUG BREAKDOWN DATA BY TYPE
4.1 Global Acute Hepatic Porphyria Drug Historic Market Size by Type (2018-2023)
4.2 Global Acute Hepatic Porphyria Drug Forecasted Market Size by Type (2024-2029)
5 ACUTE HEPATIC PORPHYRIA DRUG BREAKDOWN DATA BY APPLICATION
5.1 Global Acute Hepatic Porphyria Drug Historic Market Size by Application (2018-2023)
5.2 Global Acute Hepatic Porphyria Drug Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Acute Hepatic Porphyria Drug Market Size (2018-2029)
6.2 North America Acute Hepatic Porphyria Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Acute Hepatic Porphyria Drug Market Size by Country (2018-2023)
6.4 North America Acute Hepatic Porphyria Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Acute Hepatic Porphyria Drug Market Size (2018-2029)
7.2 Europe Acute Hepatic Porphyria Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Acute Hepatic Porphyria Drug Market Size by Country (2018-2023)
7.4 Europe Acute Hepatic Porphyria Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Acute Hepatic Porphyria Drug Market Size (2018-2029)
8.2 Asia-Pacific Acute Hepatic Porphyria Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Acute Hepatic Porphyria Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Acute Hepatic Porphyria Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Acute Hepatic Porphyria Drug Market Size (2018-2029)
9.2 Latin America Acute Hepatic Porphyria Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Acute Hepatic Porphyria Drug Market Size by Country (2018-2023)
9.4 Latin America Acute Hepatic Porphyria Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Acute Hepatic Porphyria Drug Market Size (2018-2029)
10.2 Middle East & Africa Acute Hepatic Porphyria Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Detail
11.1.2 Alnylam Pharmaceuticals Business Overview
11.1.3 Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Introduction
11.1.4 Alnylam Pharmaceuticals Revenue in Acute Hepatic Porphyria Drug Business (2018-2023)
11.1.5 Alnylam Pharmaceuticals Recent Development
11.2 Recordati Rare Diseases
11.2.1 Recordati Rare Diseases Company Detail
11.2.2 Recordati Rare Diseases Business Overview
11.2.3 Recordati Rare Diseases Acute Hepatic Porphyria Drug Introduction
11.2.4 Recordati Rare Diseases Revenue in Acute Hepatic Porphyria Drug Business (2018-2023)
11.2.5 Recordati Rare Diseases Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 350 Mg
1.2.3 313 Mg
1.3 Market by Application
1.3.1 Global Acute Hepatic Porphyria Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Acute Hepatic Porphyria Drug Market Perspective (2018-2029)
2.2 Acute Hepatic Porphyria Drug Growth Trends by Region
2.2.1 Global Acute Hepatic Porphyria Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Acute Hepatic Porphyria Drug Historic Market Size by Region (2018-2023)
2.2.3 Acute Hepatic Porphyria Drug Forecasted Market Size by Region (2024-2029)
2.3 Acute Hepatic Porphyria Drug Market Dynamics
2.3.1 Acute Hepatic Porphyria Drug Industry Trends
2.3.2 Acute Hepatic Porphyria Drug Market Drivers
2.3.3 Acute Hepatic Porphyria Drug Market Challenges
2.3.4 Acute Hepatic Porphyria Drug Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Acute Hepatic Porphyria Drug Players by Revenue
3.1.1 Global Top Acute Hepatic Porphyria Drug Players by Revenue (2018-2023)
3.1.2 Global Acute Hepatic Porphyria Drug Revenue Market Share by Players (2018-2023)
3.2 Global Acute Hepatic Porphyria Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Hepatic Porphyria Drug Revenue
3.4 Global Acute Hepatic Porphyria Drug Market Concentration Ratio
3.4.1 Global Acute Hepatic Porphyria Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Hepatic Porphyria Drug Revenue in 2022
3.5 Acute Hepatic Porphyria Drug Key Players Head office and Area Served
3.6 Key Players Acute Hepatic Porphyria Drug Product Solution and Service
3.7 Date of Enter into Acute Hepatic Porphyria Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ACUTE HEPATIC PORPHYRIA DRUG BREAKDOWN DATA BY TYPE
4.1 Global Acute Hepatic Porphyria Drug Historic Market Size by Type (2018-2023)
4.2 Global Acute Hepatic Porphyria Drug Forecasted Market Size by Type (2024-2029)
5 ACUTE HEPATIC PORPHYRIA DRUG BREAKDOWN DATA BY APPLICATION
5.1 Global Acute Hepatic Porphyria Drug Historic Market Size by Application (2018-2023)
5.2 Global Acute Hepatic Porphyria Drug Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Acute Hepatic Porphyria Drug Market Size (2018-2029)
6.2 North America Acute Hepatic Porphyria Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Acute Hepatic Porphyria Drug Market Size by Country (2018-2023)
6.4 North America Acute Hepatic Porphyria Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Acute Hepatic Porphyria Drug Market Size (2018-2029)
7.2 Europe Acute Hepatic Porphyria Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Acute Hepatic Porphyria Drug Market Size by Country (2018-2023)
7.4 Europe Acute Hepatic Porphyria Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Acute Hepatic Porphyria Drug Market Size (2018-2029)
8.2 Asia-Pacific Acute Hepatic Porphyria Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Acute Hepatic Porphyria Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Acute Hepatic Porphyria Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Acute Hepatic Porphyria Drug Market Size (2018-2029)
9.2 Latin America Acute Hepatic Porphyria Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Acute Hepatic Porphyria Drug Market Size by Country (2018-2023)
9.4 Latin America Acute Hepatic Porphyria Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Acute Hepatic Porphyria Drug Market Size (2018-2029)
10.2 Middle East & Africa Acute Hepatic Porphyria Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Detail
11.1.2 Alnylam Pharmaceuticals Business Overview
11.1.3 Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Introduction
11.1.4 Alnylam Pharmaceuticals Revenue in Acute Hepatic Porphyria Drug Business (2018-2023)
11.1.5 Alnylam Pharmaceuticals Recent Development
11.2 Recordati Rare Diseases
11.2.1 Recordati Rare Diseases Company Detail
11.2.2 Recordati Rare Diseases Business Overview
11.2.3 Recordati Rare Diseases Acute Hepatic Porphyria Drug Introduction
11.2.4 Recordati Rare Diseases Revenue in Acute Hepatic Porphyria Drug Business (2018-2023)
11.2.5 Recordati Rare Diseases Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of 350 Mg
Table 3. Key Players of 313 Mg
Table 4. Global Acute Hepatic Porphyria Drug Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Acute Hepatic Porphyria Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Acute Hepatic Porphyria Drug Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Acute Hepatic Porphyria Drug Market Share by Region (2018-2023)
Table 8. Global Acute Hepatic Porphyria Drug Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Acute Hepatic Porphyria Drug Market Share by Region (2024-2029)
Table 10. Acute Hepatic Porphyria Drug Market Trends
Table 11. Acute Hepatic Porphyria Drug Market Drivers
Table 12. Acute Hepatic Porphyria Drug Market Challenges
Table 13. Acute Hepatic Porphyria Drug Market Restraints
Table 14. Global Acute Hepatic Porphyria Drug Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Acute Hepatic Porphyria Drug Market Share by Players (2018-2023)
Table 16. Global Top Acute Hepatic Porphyria Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Hepatic Porphyria Drug as of 2022)
Table 17. Ranking of Global Top Acute Hepatic Porphyria Drug Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Acute Hepatic Porphyria Drug Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Acute Hepatic Porphyria Drug Product Solution and Service
Table 21. Date of Enter into Acute Hepatic Porphyria Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Acute Hepatic Porphyria Drug Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Acute Hepatic Porphyria Drug Revenue Market Share by Type (2018-2023)
Table 25. Global Acute Hepatic Porphyria Drug Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Acute Hepatic Porphyria Drug Revenue Market Share by Type (2024-2029)
Table 27. Global Acute Hepatic Porphyria Drug Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2018-2023)
Table 29. Global Acute Hepatic Porphyria Drug Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2024-2029)
Table 31. North America Acute Hepatic Porphyria Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Acute Hepatic Porphyria Drug Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Acute Hepatic Porphyria Drug Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Acute Hepatic Porphyria Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Acute Hepatic Porphyria Drug Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Acute Hepatic Porphyria Drug Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Acute Hepatic Porphyria Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Acute Hepatic Porphyria Drug Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Acute Hepatic Porphyria Drug Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Acute Hepatic Porphyria Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Acute Hepatic Porphyria Drug Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Acute Hepatic Porphyria Drug Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Acute Hepatic Porphyria Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2024-2029) & (US$ Million)
Table 46. Alnylam Pharmaceuticals Company Detail
Table 47. Alnylam Pharmaceuticals Business Overview
Table 48. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Product
Table 49. Alnylam Pharmaceuticals Revenue in Acute Hepatic Porphyria Drug Business (2018-2023) & (US$ Million)
Table 50. Alnylam Pharmaceuticals Recent Development
Table 51. Recordati Rare Diseases Company Detail
Table 52. Recordati Rare Diseases Business Overview
Table 53. Recordati Rare Diseases Acute Hepatic Porphyria Drug Product
Table 54. Recordati Rare Diseases Revenue in Acute Hepatic Porphyria Drug Business (2018-2023) & (US$ Million)
Table 55. Recordati Rare Diseases Recent Development
Table 56. Research Programs/Design for This Report
Table 57. Key Data Information from Secondary Sources
Table 58. Key Data Information from Primary Sources
Table 1. Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of 350 Mg
Table 3. Key Players of 313 Mg
Table 4. Global Acute Hepatic Porphyria Drug Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Acute Hepatic Porphyria Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Acute Hepatic Porphyria Drug Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Acute Hepatic Porphyria Drug Market Share by Region (2018-2023)
Table 8. Global Acute Hepatic Porphyria Drug Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Acute Hepatic Porphyria Drug Market Share by Region (2024-2029)
Table 10. Acute Hepatic Porphyria Drug Market Trends
Table 11. Acute Hepatic Porphyria Drug Market Drivers
Table 12. Acute Hepatic Porphyria Drug Market Challenges
Table 13. Acute Hepatic Porphyria Drug Market Restraints
Table 14. Global Acute Hepatic Porphyria Drug Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Acute Hepatic Porphyria Drug Market Share by Players (2018-2023)
Table 16. Global Top Acute Hepatic Porphyria Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Hepatic Porphyria Drug as of 2022)
Table 17. Ranking of Global Top Acute Hepatic Porphyria Drug Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Acute Hepatic Porphyria Drug Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Acute Hepatic Porphyria Drug Product Solution and Service
Table 21. Date of Enter into Acute Hepatic Porphyria Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Acute Hepatic Porphyria Drug Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Acute Hepatic Porphyria Drug Revenue Market Share by Type (2018-2023)
Table 25. Global Acute Hepatic Porphyria Drug Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Acute Hepatic Porphyria Drug Revenue Market Share by Type (2024-2029)
Table 27. Global Acute Hepatic Porphyria Drug Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2018-2023)
Table 29. Global Acute Hepatic Porphyria Drug Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2024-2029)
Table 31. North America Acute Hepatic Porphyria Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Acute Hepatic Porphyria Drug Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Acute Hepatic Porphyria Drug Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Acute Hepatic Porphyria Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Acute Hepatic Porphyria Drug Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Acute Hepatic Porphyria Drug Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Acute Hepatic Porphyria Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Acute Hepatic Porphyria Drug Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Acute Hepatic Porphyria Drug Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Acute Hepatic Porphyria Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Acute Hepatic Porphyria Drug Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Acute Hepatic Porphyria Drug Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Acute Hepatic Porphyria Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2024-2029) & (US$ Million)
Table 46. Alnylam Pharmaceuticals Company Detail
Table 47. Alnylam Pharmaceuticals Business Overview
Table 48. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Product
Table 49. Alnylam Pharmaceuticals Revenue in Acute Hepatic Porphyria Drug Business (2018-2023) & (US$ Million)
Table 50. Alnylam Pharmaceuticals Recent Development
Table 51. Recordati Rare Diseases Company Detail
Table 52. Recordati Rare Diseases Business Overview
Table 53. Recordati Rare Diseases Acute Hepatic Porphyria Drug Product
Table 54. Recordati Rare Diseases Revenue in Acute Hepatic Porphyria Drug Business (2018-2023) & (US$ Million)
Table 55. Recordati Rare Diseases Recent Development
Table 56. Research Programs/Design for This Report
Table 57. Key Data Information from Secondary Sources
Table 58. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Acute Hepatic Porphyria Drug Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Acute Hepatic Porphyria Drug Market Share by Type: 2022 VS 2029
Figure 3. 350 Mg Features
Figure 4. 313 Mg Features
Figure 5. Global Acute Hepatic Porphyria Drug Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Acute Hepatic Porphyria Drug Market Share by Application: 2022 VS 2029
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Online Pharmacy Case Studies
Figure 10. Others Case Studies
Figure 11. Acute Hepatic Porphyria Drug Report Years Considered
Figure 12. Global Acute Hepatic Porphyria Drug Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Acute Hepatic Porphyria Drug Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Acute Hepatic Porphyria Drug Market Share by Region: 2022 VS 2029
Figure 15. Global Acute Hepatic Porphyria Drug Market Share by Players in 2022
Figure 16. Global Top Acute Hepatic Porphyria Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Hepatic Porphyria Drug as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Acute Hepatic Porphyria Drug Revenue in 2022
Figure 18. North America Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Acute Hepatic Porphyria Drug Market Share by Country (2018-2029)
Figure 20. United States Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Acute Hepatic Porphyria Drug Market Share by Country (2018-2029)
Figure 24. Germany Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Acute Hepatic Porphyria Drug Market Share by Region (2018-2029)
Figure 32. China Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Acute Hepatic Porphyria Drug Market Share by Country (2018-2029)
Figure 40. Mexico Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Acute Hepatic Porphyria Drug Market Share by Country (2018-2029)
Figure 44. Turkey Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Alnylam Pharmaceuticals Revenue Growth Rate in Acute Hepatic Porphyria Drug Business (2018-2023)
Figure 47. Recordati Rare Diseases Revenue Growth Rate in Acute Hepatic Porphyria Drug Business (2018-2023)
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
Figure 1. Global Acute Hepatic Porphyria Drug Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Acute Hepatic Porphyria Drug Market Share by Type: 2022 VS 2029
Figure 3. 350 Mg Features
Figure 4. 313 Mg Features
Figure 5. Global Acute Hepatic Porphyria Drug Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Acute Hepatic Porphyria Drug Market Share by Application: 2022 VS 2029
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Online Pharmacy Case Studies
Figure 10. Others Case Studies
Figure 11. Acute Hepatic Porphyria Drug Report Years Considered
Figure 12. Global Acute Hepatic Porphyria Drug Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Acute Hepatic Porphyria Drug Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Acute Hepatic Porphyria Drug Market Share by Region: 2022 VS 2029
Figure 15. Global Acute Hepatic Porphyria Drug Market Share by Players in 2022
Figure 16. Global Top Acute Hepatic Porphyria Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Hepatic Porphyria Drug as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Acute Hepatic Porphyria Drug Revenue in 2022
Figure 18. North America Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Acute Hepatic Porphyria Drug Market Share by Country (2018-2029)
Figure 20. United States Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Acute Hepatic Porphyria Drug Market Share by Country (2018-2029)
Figure 24. Germany Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Acute Hepatic Porphyria Drug Market Share by Region (2018-2029)
Figure 32. China Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Acute Hepatic Porphyria Drug Market Share by Country (2018-2029)
Figure 40. Mexico Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Acute Hepatic Porphyria Drug Market Share by Country (2018-2029)
Figure 44. Turkey Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Acute Hepatic Porphyria Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Alnylam Pharmaceuticals Revenue Growth Rate in Acute Hepatic Porphyria Drug Business (2018-2023)
Figure 47. Recordati Rare Diseases Revenue Growth Rate in Acute Hepatic Porphyria Drug Business (2018-2023)
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
